SCOPUS BIOPHARMA INC (SCPS) Stock Price & Overview

NASDAQ:SCPSUS8091711015

Current stock price

0.1682 USD
-0.17 (-50.54%)
At close:
0.12 USD
-0.05 (-28.66%)
After Hours:

The current stock price of SCPS is 0.1682 USD. Today SCPS is down by -50.54%. In the past month the price decreased by -30.61%. In the past year, price decreased by -91.55%.

SCPS Key Statistics

52-Week Range0.1682 - 2.11
Current SCPS stock price positioned within its 52-week range.
1-Month Range0.1682 - 0.5794
Current SCPS stock price positioned within its 1-month range.
Market Cap
3.548M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.81
Dividend Yield
N/A

SCPS Stock Performance

Today
-50.54%
1 Week
-23.55%
1 Month
-30.61%
3 Months
-41.19%
Longer-term
6 Months -60.42%
1 Year -91.55%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

SCPS Stock Chart

SCOPUS BIOPHARMA INC / SCPS Daily stock chart

SCPS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SCPS. When comparing the yearly performance of all stocks, SCPS is a bad performer in the overall market: 93.7% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SCPS Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SCPS. SCPS may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SCPS Earnings

Next Earnings DateN/A
Last Earnings DateDec 2, 2022
PeriodQ3 / 2022
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

SCPS Forecast & Estimates

7 analysts have analysed SCPS and the average price target is 12.24 USD. This implies a price increase of 7177.05% is expected in the next year compared to the current price of 0.1682.


Analysts
Analysts82.86
Price Target12.24 (7177.05%)
EPS Next Y8.21%
Revenue Next YearN/A

SCPS Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

SCPS Financial Highlights

Over the last trailing twelve months SCPS reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 40.08% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-16.40M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-10.22%
Sales Q2Q%N/A
EPS 1Y (TTM)40.08%
Revenue 1Y (TTM)N/A

SCPS Ownership

Ownership
Inst Owners0%
Shares21.09M
Float7.17M
Ins Owners2.42%
Short Float %0.15%
Short Ratio0.01

About SCPS

Company Profile

SCPS logo image Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.

Company Info

IPO: 2020-12-16

SCOPUS BIOPHARMA INC

420 Lexington Ave Rm 300

New York City NEW YORK US

Employees: 9

SCPS Company Website

Phone: 12124792513.0

SCOPUS BIOPHARMA INC / SCPS FAQ

Can you describe the business of SCOPUS BIOPHARMA INC?

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.


What is the stock price of SCOPUS BIOPHARMA INC today?

The current stock price of SCPS is 0.1682 USD. The price decreased by -50.54% in the last trading session.


Does SCPS stock pay dividends?

SCPS does not pay a dividend.


What is the ChartMill technical and fundamental rating of SCPS stock?

SCPS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the Price/Earnings (PE) ratio of SCOPUS BIOPHARMA INC (SCPS)?

SCOPUS BIOPHARMA INC (SCPS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).


What is the market capitalization of SCPS stock?

SCOPUS BIOPHARMA INC (SCPS) has a market capitalization of 3.55M USD. This makes SCPS a Nano Cap stock.


What is the ownership structure of SCOPUS BIOPHARMA INC (SCPS)?

You can find the ownership structure of SCOPUS BIOPHARMA INC (SCPS) on the Ownership tab.